Myelofibrosis Clinical Trial Update: The Science Behind JAK Inhibitors

Myelofibrosis Clinical Trial Update: The Science Behind JAK Inhibitors

P2Professional

2 years
2,760 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
With the knowledge clinicians are gaining about the driver mutations of myeloproliferative neoplasms (MPNs), JAK inhibitors have become more recognized as a personalized, targeted therapy. But how do JAK inhibitors actually work? Dr. David Snyder from City of Hope explains what these medicines actual inhibit and goes on to discuss different variations of JAK inhibitors. Dr. Snyder shares information about approved JAK inhibitors and others in clinical trials, such as the PAC203 trial for pacritinib.

Get email alerts | http://www.patientpower.info/alerts

Subscribe on YouTube | http://www.youtube.com/patientpower
Like on Facebook | http://www.fb.com/patientpower.info
Follow on Twitter | http://www.twitter.com/patientpower
Follow on Google+ | http://www.google.com/+patientpowerinfo
Up Next Autoplay